FDA 核准合併使用Encorafenib (Braftovi)及Binimetinib ... | 合法藥品大搜索

試驗計畫標題（名稱）, 一項多中心、隨機分配、開放式、3 組別第3 期試驗，以Encorafenib + Cetuximab 併用或未併用Binimetinib，與Irinotecan/Cetuximab 或 ... Read More

Encorafenib (trade name Braftovi) is a drug for the treatment of certain melanomas. It is a small molecule BRAF inhibitor that targets key enzymes in the MAPK ... Read More

2020年4月8日 — FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation. Read More

2018年7月25日 — 於2018年6月27日，美國FDA核准了合併使用BRAF抑制劑Encorafenib及MEK抑制劑Binimetinib於無法切除或轉移並帶有BRAF V600E/V600K之 ... Read More

Drug interaction overview · Encorafenib is a reversible inhibitor of UGT1A1, CYP1A2, CYP2B6, CYP2C8/9, CYP2D6, and CYP3A, and a time-dependent inhibitor of ... Read More

Encorafenib is a selective inhibitor of BRAF kinase that is used in combination with binimetinib, an inhibitor of MEK, in the therapy of metastatic and advanced ... Read More

Encorafenib is indicated: - in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation ... Read More

Summary. Encorafenib is a kinase inhibitor used to treat unresectable or metastatic melanoma with specific mutations. Brand Names. Braftovi. Read More

由 J Tabernero 著作 · 2021 · 被引用 13 次 — In the BEACON CRC study, encorafenib plus cetuximab improved OS, ORR, and progression-free survival in previously treated patients in the ... Read More

由 J Tabernero 著作 · 2021 · 被引用 13 次 — Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated ... Read More